Synedgen uses the science of glycomics – the study of complex sugar structure and function – to discover and develop ultra-purified therapeutic polysaccharides that are soluble, active, and targeted in the human body. These new molecular entities are designed to alter the progression of diseases that currently have limited treatment options, and improve the lives of patients.
February 15, 2018
Synedgen Expands Research Focus to broaden indications for core platform of novel pharmaceuticals — Appoints New Senior Scientist to lead research and discovery team
January 31, 2018
Synedgen Announces Publication of Study Exploring the Role of Biological Ions in Controlling Mucosal Surfaces
October 27, 2016
Synedgen Announces Presentation of Data at NACFC Demonstrating Prevention of Gastrointestinal Complications with Glycopolymer-Based Therapeutics in a Preclinical Model of Cystic Fibrosis